Assessment of RANKL/RANK/osteoprotegerin system expression in patients with hepatocellular carcinoma

Minerva Endocrinol (Torino). 2021 Sep;46(3):367-369. doi: 10.23736/S2724-6507.20.03163-6. Epub 2020 Jul 3.

Authors

Manuela Cabiati¹, Melania Gaggini¹, Paolo DE Simone², Giuseppina Basta¹, Amalia Gastaldelli¹, Silvia Del Ry³

Affiliations

¹ Institute of Clinical Physiology, Italian Research Council (CNR), Pisa, Italy.
² Department of Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy.
³ Institute of Clinical Physiology, Italian Research Council (CNR), Pisa, Italy - delry@ifc.cnr.it.

PMID: 32623844
DOI: 10.23736/S2724-6507.20.03163-6

No abstract available

MeSH terms

Carcinoma, Hepatocellular*
Humans
Liver Neoplasms*
Osteoprotegerin*
RANK Ligand*
Receptor Activator of Nuclear Factor-kappa B*

Substances

Osteoprotegerin
RANK Ligand
Receptor Activator of Nuclear Factor-kappa B
TNFRSF11A protein, human
TNFRSF11B protein, human
TNFSF11 protein, human